Professor | Wei-Fu Lv | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Wei-Fu Lv
Contact Information	weifulv@ustc.edu.cn
Language ability	Chinese, English
Province	Anhui

Upload Avatar (500 x 500)

Name

Wei-Fu Lv

Contact Information

weifulv@ustc.edu.cn

Language ability

Chinese, English

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	1990/08–1993/07 Master's Degree: Third Military Medical University, China 2012/09–2015/06 Doctoral Degree: Shandong University, China Received 6 provincial and ministerial science and technology progress awards Published over 20 papers in SCI journals such as Lancet Oncology
Work Experience	1984/08-1990/07 - Hefei Second People's Hospital - Physician 1993/08-1998/10 - PLA 254 Hospital - Attending Physician 1999/11-present - First Affiliated Hospital of USTC - Chief Physician, Professor
Awards	Provincial and Ministerial Science and Technology Progress Award: 6 times

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

1990/08–1993/07 Master's Degree: Third Military Medical University, China
2012/09–2015/06 Doctoral Degree: Shandong University, China
Received 6 provincial and ministerial science and technology progress awards
Published over 20 papers in SCI journals such as Lancet Oncology

Work Experience

1984/08-1990/07 - Hefei Second People's Hospital - Physician
1993/08-1998/10 - PLA 254 Hospital - Attending Physician
1999/11-present - First Affiliated Hospital of USTC - Chief Physician, Professor

Awards

Provincial and Ministerial Science and Technology Progress Award: 6 times

Areas of Focus	Research on the mechanism of drug-loaded microspheres in transcatheter arterial chemoembolization for malignant tumors Changes in gut microbiota after interventional treatment of liver cancer and their role and mechanism in disease progression Clinical research and related mechanisms of TACE combined with targeted and immunotherapy for liver cancer Application and evaluation of new biomaterials in interventional therapy
Publications	Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma, Liu KC, Hao YH, Lv WF, Jia WD, Ji CS, Zhou CZ, Cheng DL, Xu SB, Gao ZG, Su MX, Shi CS, 2020 Interventional Treatment Strategy for Primary Budd-Chiari Syndrome with Both Inferior Vena Cava and Hepatic Vein Involvement: Patients from Two Centers in China, Cheng DL, Xu H, Li CL, Lv WF, Li CT, Mukhiya G, Fang WW, 2019 CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity, Liu KC, Xu P, Lv WF, Qiu XH, Yao JL, Gu JF, Wei W, 2020 Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial, Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, Li HL, Wang WH, Li YL, Ni CF, Shi HB, Xiao EH, Lv WF, Sun JH, Xu K, Han GH, Du LA, Ren WX, Li MQ, Mao AW, Xiang H, Zhang KX, Min J, Zhu GY, Su C, Chen L, Teng GJ, 2018 FLT3/FLT3L-mediated CD103+ dendritic cells alleviates hepatic ischemia-reperfusion injury in mice via activation of treg cells, Zhou CZ, Wang RF, Cheng DL, Zhu YJ, Cao Q, Lv WF, 2019 Early Warning Models to Estimate the 30-Day Mortality Risk After Stent Placement for Patients with Malignant Biliary Obstruction, Zhou HF, Lu J, Zhu HD, Guo JH, Huang M, Ji JS, Lv WF, Li YL, Xu H, Chen L, Zhu GY, Teng GJ, 2019 Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis, Wei-fu Lv, Dong Lu, Kai-Cai Liu, et al., 2018 Liver Abscess Formation Following Transarterial Chemoembolization: Clinical Features, Risk Factors, Bacteria Spectrum, and Percutaneous Catheter Drainage, Wei-fu Lv, Dong Lu, Yu-sheng He, et al., 2016

Areas of Focus

Research on the mechanism of drug-loaded microspheres in transcatheter arterial chemoembolization for malignant tumors
Changes in gut microbiota after interventional treatment of liver cancer and their role and mechanism in disease progression
Clinical research and related mechanisms of TACE combined with targeted and immunotherapy for liver cancer
Application and evaluation of new biomaterials in interventional therapy

Publications

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma, Liu KC, Hao YH, Lv WF*, Jia WD, Ji CS, Zhou CZ, Cheng DL, Xu SB, Gao ZG, Su MX, Shi CS, 2020
Interventional Treatment Strategy for Primary Budd-Chiari Syndrome with Both Inferior Vena Cava and Hepatic Vein Involvement: Patients from Two Centers in China, Cheng DL, Xu H, Li CL, Lv WF, Li CT, Mukhiya G, Fang WW, 2019
CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity, Liu KC, Xu P, Lv WF*, Qiu XH, Yao JL, Gu JF, Wei W, 2020
Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial, Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, Li HL, Wang WH, Li YL, Ni CF, Shi HB, Xiao EH, Lv WF, Sun JH, Xu K, Han GH, Du LA, Ren WX, Li MQ, Mao AW, Xiang H, Zhang KX, Min J, Zhu GY, Su C, Chen L, Teng GJ, 2018
FLT3/FLT3L-mediated CD103+ dendritic cells alleviates hepatic ischemia-reperfusion injury in mice via activation of treg cells, Zhou CZ, Wang RF, Cheng DL, Zhu YJ, Cao Q, Lv WF*, 2019
Early Warning Models to Estimate the 30-Day Mortality Risk After Stent Placement for Patients with Malignant Biliary Obstruction, Zhou HF, Lu J, Zhu HD, Guo JH, Huang M, Ji JS, Lv WF*, Li YL, Xu H, Chen L, Zhu GY, Teng GJ, 2019
Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis, Wei-fu Lv*, Dong Lu, Kai-Cai Liu, et al., 2018
Liver Abscess Formation Following Transarterial Chemoembolization: Clinical Features, Risk Factors, Bacteria Spectrum, and Percutaneous Catheter Drainage, Wei-fu Lv*, Dong Lu, Yu-sheng He, et al., 2016

Drug-Loaded Microspheres Transcatheter Arterial Chemoembolization Malignant Tumors Mechanism Liver Cancer Gut Microbiota Disease Progression Tace Targeted Therapy Immunotherapy

Bairong Xia - University of Science and Technology of China

Xingbing Wang - University of Science and Technology of China

Yifu He - University of Science and Technology of China

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us